Trial Profile
A 12 month open-label, randomized, multicenter, sequential cohort-group, dose finding study to evaluate the efficacy, safety and tolerability of oral AEB071 versus cyclosporine in combination with everolimus, basiliximab and corticosteroids in de novo adult renal transplant recipients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Apr 2015
Price :
$35
*
At a glance
- Drugs Sotrastaurin (Primary) ; Basiliximab; Ciclosporin; Corticosteroids; Everolimus
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 01 May 2012 Primary endpoint 'Clinical-failure-rate' has not been met.
- 15 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (NCT00504543).
- 01 Nov 2011 Planned End Date changed from 1 Mar 2011 to 1 Apr 2011 as reported by ClinicalTrials.gov. (parent trial: NCT00504543).